IL6 and renal cell carcinoma: In patients with advanced RCC receiving chemoIO, 72% with baseline serum IL‐6 < 6.5 pg/mL did not have disease progression at 12 months, whereas 41% with high serum IL‐6 remained progression‐free at the same timepoint.30